{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:29:34Z","timestamp":1794547774983,"version":"4.9.1"},"reference-count":23,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T00:00:00Z","timestamp":1448323200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Dermatology"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>This study sought to develop a therapeutic algorithm for selecting the optimal systemic drugs to treat moderate to severe psoriasis, based on the patient's Psoriasis Area Severity Index (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content>) score. Data from 191 patients undergoing treatment for plaque psoriasis were retrospectively analyzed. Pre\u2010 and post\u2010treatment <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> scores were compared across patients treated with acitretin of retinoic acid (<jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content>;<jats:italic> n<\/jats:italic> = 95), methotrexate (<jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content>;<jats:italic> n<\/jats:italic> = 41) or cyclosporin A (CsA; <jats:italic>n<\/jats:italic> = 55). The <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> score improvement was examined at weeks 4 (primary end\u2010point) and 12 (secondary end\u2010point). <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> and CsA had a higher global therapeutic efficacy, with more patients exhibiting a marked improvement (\u226575% improvement in <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> [<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75]) at week 12 with <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> (56.1%, <jats:italic>P =<\/jats:italic> 0.028) and CsA (54.5%, <jats:italic>P =<\/jats:italic> 0.025) than <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> (35.8%). Multivariate analysis adjusting for confounders produced consistent results (<jats:italic>P<\/jats:italic> = 0.026). For patients with severe psoriasis (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> &gt;12), the <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 75 response was higher with CsA (55.6%) than <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> (31.5%) (<jats:italic>P<\/jats:italic> = 0.023) at week 4 and higher with <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> (57.1%, <jats:italic>P<\/jats:italic> = 0.029) and CsA (61.5%, <jats:italic>P<\/jats:italic> = 0.017) than <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> (21.7%) at week 12. Because <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is a standard systemic drug, the <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> group was divided into two subgroups based on the <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> 50 response at week 12. Marked or moderate improvement (<jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> \u226550) with <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> was observed in patients with a pretreatment <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> score less than 14. Thus, oral <jats:styled-content style=\"fixed-case\">RA<\/jats:styled-content> is recommended as a first\u2010line drug for patients with <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> of less than 14, and <jats:styled-content style=\"fixed-case\">MTX<\/jats:styled-content> or CsA are recommended for patients with <jats:styled-content style=\"fixed-case\">PASI<\/jats:styled-content> of 14 or more.<\/jats:p>","DOI":"10.1111\/1346-8138.13195","type":"journal-article","created":{"date-parts":[[2015,11,24]],"date-time":"2015-11-24T11:46:52Z","timestamp":1448365612000},"page":"643-649","source":"Crossref","is-referenced-by-count":6,"title":["Algorithm to select optimal systemic anti\u2010psoriatic drugs in relation with patients' Psoriasis Area and Severity Index score for plaque psoriasis"],"prefix":"10.1111","volume":"43","author":[{"given":"Soo Hyeon","family":"Bae","sequence":"first","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sook Jung","family":"Yun","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee\u2010Bum","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong\u2010Jin","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Ho","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung\u2010Chul","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Dermatology Chonnam National University Medical School Gwangju Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,11,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2001.00832.x"},{"key":"e_1_2_6_3_1","first-page":"1","article-title":"Therapy of moderate and severe psoriasis","volume":"2","author":"Claes C","year":"2006","journal-title":"GMS Health Techno Assess"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2008.03753.x"},{"key":"e_1_2_6_5_1","first-page":"4","article-title":"Review of Conventional Systemic Therapies for Severe Psoriasis","volume":"7","author":"Thomas DR","year":"2011","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_6_6_1","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1684\/ejd.2009.0725","article-title":"Cost\u2010effectiveness of biologics for moderate\u2010to\u2010severe psoriasis from the perspective of the Swiss healthcare system","volume":"19","author":"Greiner RA","year":"2009","journal-title":"Eur J Dermatol"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1159\/000083509"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2007.11.006"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/jdt.14.s2.7.16"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.5507\/bp.2012.007"},{"key":"e_1_2_6_11_1","first-page":"277","article-title":"Short term methotrexate therapy in psoriasis","volume":"100","author":"Kumar B","year":"1994","journal-title":"Indian J Med Res"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03693.x"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.jid.5700808"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.38331"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.16"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08898.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200304070-00006"},{"key":"e_1_2_6_18_1","first-page":"1247","article-title":"The Efficacy and Safety of Re\u2010PUVA Combination Therapy for Psoriasis in Comparison with Retinoid and PUVA Monotherapy","volume":"37","author":"Park S\u2010B","year":"1999","journal-title":"Korean J Dermatol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08564.x"},{"key":"e_1_2_6_20_1","first-page":"1","article-title":"Efficacy of acitretin in severe psoriasis","volume":"8","author":"Geiger JM","year":"2003","journal-title":"Skin Therapy Lett"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1921"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.09755.x"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70406-8"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1995.01690190043008"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1346-8138.13195","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1346-8138.13195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T15:53:27Z","timestamp":1695570807000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1346-8138.13195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,24]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1111\/1346-8138.13195"],"URL":"https:\/\/doi.org\/10.1111\/1346-8138.13195","archive":["Portico"],"relation":{},"ISSN":["0385-2407","1346-8138"],"issn-type":[{"value":"0385-2407","type":"print"},{"value":"1346-8138","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,24]]}}}